We are international
• treatment options TEXT SIZE   
novel therapies    back


Kyprolis® (carfilzomib) was first approved by the FDA in 2012 for the treatment of patients with myeloma who have received at least two prior therapies, including the proteasome inhibitor Velcade® (bortezomib) and an immunomodulatory drug (IMiD®), Revlimid® (lenalidomide) or Thalomid® (thalidomide), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

On July, 24, 2015, the FDA approved Kyprolis given in combination with Revlimid® (lenalidomide) and dexamethasone to treat patients with relapsed multiple myeloma who have previously received at least one prior treatment.

On September 18, 2015, the FDA granted priority review of a supplemental new drug application to expand the indication for Kyprolis in combination with dexamethasone to include the treatment of patients who have received at least one prior therapy. The FDA will announce its decision on this application by January, 2016.

General Information
Clinical Trials
Blogs and Press Releases
Kyprolis®; for Injection Tip Card
Onyx Pharmaceuticals 360™ (Onyx 360)
Onyx 360 is a comprehensive patient and caregiver support and services program designed to help patients navigate the treatment journey, including reimbursement and payment support, treatment support and referrals to third-party organizations for day-to-day and emotional support.

Understanding Kyprolis®; (carfilzomib) for Injection
This booklet discusses Kyprolis, the results of clinical trials with Kyprolis, how and when it is administered, its possible side effects, and how to manage them.